Wall Street brokerages expect Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN – Get Rating) to post $0.27 earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Supernus Pharmaceuticals’ earnings. The lowest EPS estimate is $0.17 and the highest is $0.36. Supernus Pharmaceuticals posted earnings per share of $0.11 in the same quarter last year, which would indicate a positive year-over-year growth rate of 145.5%. The company is scheduled to announce its next earnings results on Monday, January 1st.
On average, analysts expect that Supernus Pharmaceuticals will report full-year earnings of $1.58 per share for the current financial year, with EPS estimates ranging from $1.37 to $1.80. For the next fiscal year, analysts anticipate that the company will post earnings of $0.97 per share, with EPS estimates ranging from $0.25 to $1.44. Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side research firms that cover Supernus Pharmaceuticals.
Supernus Pharmaceuticals (NASDAQ:SUPN – Get Rating) last posted its quarterly earnings results on Wednesday, April 13th. The specialty pharmaceutical company reported $0.04 EPS for the quarter, missing the consensus estimate of $0.29 by ($0.25). Supernus Pharmaceuticals had a net margin of 14.49% and a return on equity of 10.56%.
Several large investors have recently modified their holdings of SUPN. UMB Bank N A MO purchased a new stake in shares of Supernus Pharmaceuticals in the fourth quarter valued at about $29,000. Eagle Bay Advisors LLC boosted its holdings in Supernus Pharmaceuticals by 70.9% during the fourth quarter. Eagle Bay Advisors LLC now owns 1,444 shares of the specialty pharmaceutical company’s stock worth $42,000 after buying an additional 599 shares in the last quarter. First Horizon Advisors Inc. boosted its holdings in Supernus Pharmaceuticals by 1,275.9% during the fourth quarter. First Horizon Advisors Inc. now owns 1,486 shares of the specialty pharmaceutical company’s stock worth $43,000 after buying an additional 1,378 shares in the last quarter. C M Bidwell & Associates Ltd. purchased a new stake in shares of Supernus Pharmaceuticals in the fourth quarter valued at about $43,000. Finally, Banque Cantonale Vaudoise lifted its holdings in shares of Supernus Pharmaceuticals by 64.4% in the third quarter. Banque Cantonale Vaudoise now owns 1,787 shares of the specialty pharmaceutical company’s stock valued at $48,000 after purchasing an additional 700 shares in the last quarter.
SUPN stock opened at $31.10 on Friday. The company’s 50-day simple moving average is $31.48 and its 200-day simple moving average is $30.68. The company has a quick ratio of 2.59, a current ratio of 2.85 and a debt-to-equity ratio of 0.46. Supernus Pharmaceuticals has a 52-week low of $23.15 and a 52-week high of $34.50. The firm has a market cap of $1.64 billion, a P/E ratio of 31.73 and a beta of 1.10.
Supernus Pharmaceuticals Company Profile (Get Rating)
Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. Its commercial products include Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age.
- Get a free copy of the StockNews.com research report on Supernus Pharmaceuticals (SUPN)
- Levi Straus Stock Ready to Buy the Dip
- Bed Bath & Beyond Stock Ready to Scale Into
- Institutions And Analysts Drive UnitedHealth Group Higher
- MarketBeat: Week in Review 4/11 – 4/15
- Three Beaten Down Mega Caps The Analysts Are Upgrading
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.